GENEVA--(BUSINESS WIRE)--Acrongenomics Inc. (OTCBB:AGNM) announced today that it has signed a letter of intent for the acquisition of 100% of Molecular Vision Limited, (“Molecular Vision”) a private U.K. company that specializes in the development of miniaturized Point-of-Care (POC) medical diagnostic devices. The devices integrate proprietary microfluidic chips with patented organic-semiconductor technology and photodetectors to provide portable lab-quality diagnostic tests in an easy-to-use, low-cost, disposable application. These devices have the potential for multiple simultaneous testing of diagnostic markers in a wide range of applications.
